



October 24, 2024

To: All Concerned Parties

Company Name: Solasia Pharma K.K  
Representative Yoshihiro Arai, President & CEO  
((Code number: 4597, TSE Growth Section))  
Contact Toshio Miyashita, CFO, Director  
Tel 81-3-5843-8046

#### Results of important non-clinical studies of SP-05

The SP-05 originator Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) has announced the following important non-clinical study results of SP-05 (Arfolitixorin), which were presented at ENA 2024 on October 23, 2024.

<For more information, please refer to the Isofol's website.>

[https://isofolmedical.com/mfn\\_news/a-late-breaking-abstract-concerning-arfolitixorin-will-be-presented-at-ena-2024-today/](https://isofolmedical.com/mfn_news/a-late-breaking-abstract-concerning-arfolitixorin-will-be-presented-at-ena-2024-today/)

Disclaimer: The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company's actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. The information contained in this press release is for informational purposes only and should not be considered as investment solicitation. Information with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice. We do not have any obligation to update or revise any information in this press release, and any update or revision may occur anytime without notice.